Open the May 2026 issue of Nature Medicine and find the CDR132L phase 2 readout. The efficacy table is clean, well-powered, and transparently reported. Then look at the primary endpoints — left ventricular ejection fraction, cardiac structure, remodeling indices — and find the same answer across all of them: no statistically significant improvement over placebo. Cardior Pharmaceuticals built a rigorous randomized controlled trial, ran it correctly, and got a result the field needs to sit with.
That discipline matters more than it sounds. Negative data in heart failure trials has a long history of disappearing into filing cabinets. The CDR132L publication in Nature Medicine breaks that pattern — and in doing so, it hands the broader RNA therapeutics field something genuinely useful: a well-characterized failure with a mechanistic hypothesis still intact.
The Signal Behind the Miss
CDR132L is a first-in-class antisense oligonucleotide targeting miR-132, a microRNA that is upregulated in failing myocardium and drives pathological cardiac remodeling. The mechanistic rationale was credible. The Phase 1b first-in-human study — 28 patients randomized across four dose levels (0.32, 1, 3, and 10 mg/kg) administered in two IV infusions four weeks apart — found no dose-limiting toxicity and a clean safety profile. That data, published in 2021, was sufficient to justify advancing. The science said: proceed.
The phase 2 randomized trial enrolled patients with reduced left ventricular ejection fraction (HFrEF) following myocardial infarction — a post-MI remodeling population where the miR-132 pathway is mechanistically most active. That was a deliberate, defensible design choice. What the trial found was that CDR132L was again well tolerated, confirming the phase 1b safety read. What it did not find was a measurable change in the structural and functional cardiac endpoints that define clinical meaningful benefit in this population.
The gap between biological plausibility and measurable clinical effect in heart failure has consumed dozens of programs. AstraZeneca‘s mitiperstat (AZD4831), evaluated in the ENDEAVOR phase 2b/3 trial in HFpEF and HFmrEF patients, missed its co-primary endpoint on the Kansas City Cardiomyopathy Questionnaire Total Summary Score at 16 weeks in 2024 — a different mechanism, the same structural problem. Novel targets with strong preclinical rationale keep colliding with the heterogeneity and complexity of failing human myocardium.
What the Trial Design Got Right
The CDR132L phase 2 result should be read carefully before it is dismissed.
The trial was randomized, placebo-controlled, and published in full — not disclosed as a press release and quietly shelved. That transparency is not the industry norm for negative phase 2 readouts, particularly from companies that raised capital on mechanistic promise. Cardior closed a €64 million Series B in August 2021 — led by Inkef Capital, with participation from LSP, BioMedPartners, Bristol Myers Squibb, Fund+, Sunstone, Hadean Ventures, and Coparion — precisely to run the clinical program that produced this negative result. Publishing it in Nature Medicine rather than burying it is the right behavior, and the field should reward it.
The counterintuitive read here is this: the commonly held assumption is that a well-funded phase 2 miss signals a broken hypothesis. But the CDR132L data suggests something narrower — a population-selection and endpoint-sensitivity problem, not necessarily a mechanism failure. miR-132 inhibition may require a different patient population, a different dosing window relative to the acute MI event, or endpoints that capture molecular-level remodeling before structural changes become visible on imaging. The phase 1b data showed biological activity. The phase 2 trial did not deploy a design sensitive enough to catch where that activity translates — or whether the dosing interval was correctly calibrated to the remodeling timeline in this specific post-MI HFrEF cohort.
Sponsors running RNA-targeted cardiovascular programs need to absorb that distinction. The question CDR132L leaves open is not whether miR-132 is a valid target. The question is whether the current clinical measurement infrastructure — LVEF, standard echocardiographic indices — is sensitive enough to detect the early structural benefits that antisense oligonucleotide mechanisms produce on a molecular timescale. Cardiac MRI-derived strain analysis and biomarker panels tracking downstream miR-132 targets were not primary endpoints here. That design choice may have determined the outcome before the first patient was dosed.
Operational Implications for Sponsors
If you are running a first-in-class cardiovascular RNA therapeutic program, the CDR132L phase 2 result changes your endpoint strategy conversation — not just your mechanism conversation. The FDA’s Biomarker Qualification Program and the agency’s 2023 guidance on surrogate endpoints in heart failure trials both acknowledge the evolving relationship between imaging-based surrogates and clinical outcomes. But acknowledgment and operational clarity are different things. Sponsors who anchor their phase 2 primary endpoints to traditional LVEF improvements in heterogeneous post-MI populations are accepting the same detection problem Cardior just encountered. Mechanistic biomarkers — circulating miRNA levels, downstream target expression — need to be prospectively designated as primary or key secondary endpoints, not exploratory add-ons, if the intent is to understand whether the drug is actually doing what the preclinical data predicts.
The forward signal to watch is how the FDA engages with the miRNA inhibitor class as more phase 2 data accumulates. CDR132L’s clean safety profile across both the phase 1b and phase 2 studies means the tolerability case for this mechanism is now well-established across two trials and multiple dose levels. What remains operationally unresolved is whether regulators will accept a redesigned phase 2 — with molecularly-informed endpoints and a tighter post-MI enrollment window — as sufficient to justify a phase 3 investment, or whether the missed primary endpoint creates a de facto evidentiary barrier that requires a larger, longer outcomes trial to clear. That answer will define the commercialization pathway not just for CDR132L, but for every RNA-targeted cardiac program in the pipeline behind it.
References
- Nature Medicine — “The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial”
- PubMed / European Heart Journal — CDR132L Phase 1b first-in-human study (Cardior Pharmaceuticals)
- PMC / European Heart Journal — CDR132L Phase 1b safety and tolerability data, 28 patients, dose escalation
- American College of Cardiology — ENDEAVOR Trial: AZD4831 (mitiperstat) in HFpEF/HFmrEF, missed primary KCCQ-TSS endpoint, 2024
- Business Wire — Cardior Pharmaceuticals €64M Series B financing, August 25, 2021
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
